Syria's Drug Dilemma: Can the New Bosses Say No to Captagon?

The Syrian civil war saw the birth of an unexpected economic powerhouse: the drug Captagon. Under Bashar al-Assad's rule, Syria became the world's leading supplier of this stimulant, with an estimated $10 billion annual income from its sale. This turned Syria into a narco-state, with high-ranking officials, including Assad's brother Maher, allegedly overseeing production and distribution. By the mid-2010s, Syria controlled 80% of the global Captagon market, fueling conflicts and supporting Iran's regional ambitions. Now, the group controlling Damascus, Hayat Tahrir al-Sham (HTS), has set its sights on dismantling this drug trade. Their leader, Mohammed al-Jolani, argues that dismantling the Captagon trade is vital for reclaiming Syria's sovereignty. However, rooting out drug networks will be tough, as they're deeply entwined with Syria's economy. Neighbors like Jordan have already taken military action against drug warehouses, showing the region's growing concern over Captagon's spread. Iran, an ally of the former regime, heavily relies on Captagon funding for its proxies like Hezbollah. Disrupting this trade could severely impact their operations. Regional cooperation will be key, as the Captagon crisis isn't just a Syrian problem but a regional one. The Gulf states, too, are worried about rising addiction rates. Lessons from Colombia's drug war show that a multi-faceted approach is needed to tackle the issue effectively. For Syria's new leaders, tackling the Captagon trade is a chance to prove their commitment to a drug-free country. It's also a test of their ability to rebuild Syria after years of war. The road ahead is tough, but the stakes are high. Success isn't just about Syria's future but also regional security.